| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9444457d45cd90036bb780b3ad7be2fa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d21cbff64022f95c237c0bd3ec8656ca |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-243
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7135 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-243
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2019-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fab88a08176339f2285940e78a519e6c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4fd7e7110759188553cc5785b7821cd1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f66b7659d6d9dc957468bde8b8cff74a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30f052d557acbfbf61d413a3199ed22a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f53380d99149f9770ebcf92d5c2e230
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_63dcb0665148371e0d9913fadb7c0aa2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8252fd340a5e56cb219f3c79e35ca8d9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5ef5596376529b657327839ff166ffd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7693b293e4ddee1acf6cd8e4343c3b41 |
| publicationDate |
2021-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
BR-112020015520-A2 |
| titleOfInvention |
combination therapy for cancer with pentaaza macrocyclic ring complex and platinum-based anticancer agent |
| abstract |
"combination therapy for cancer with pentaaza macrocyclic ring complex and platinum-based anticancer agent". the present invention relates to a method of treating cancer in a cancer-afflicted mammal, consisting essentially of administering to the individual a therapeutically effective amount of a platinum-based anticancer agent and administering to the individual a therapeutically effective amount of a pentaaza macrocyclic ring complex corresponding to formula (i) below before, concomitantly with, or after administration of the platinum-based anticancer agent, so that the cancer response to the platinum-based anticancer agent is increased. |
| priorityDate |
2018-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |